Trial reportEuropean journal of heart failure2014
Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study.
Trial report in European journal of heart failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 73 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System
Who cites it
73 citing papers in PubMed, 4 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Effects of acute carotid baroreceptor stimulation on sympathetic nerve traffic in resistant and uncontrolled hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Pooled it
- Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.European journal of heart failure · 2022Pooled it
- The efficacy of baroreflex activation therapy for heart failure: A meta-analysis of randomized controlled trials.Medicine · 2020Pooled it
- Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review.ESC heart failure · 2020Pooled it
- Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Trial
- Impact of baroreflex activation on medical therapy optimization in heart failure: A single-center experience with electrophysiologist-led program.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Beyond Blood Pressure: Arterial Stiffness as a Hemodynamic and Neuroadrenergic Axis Linking Hypertension, Cardiac Remodeling, and Heart Failure.Life (Basel, Switzerland) · 2026Review
- The brain-heart axis: effects of cardiovascular disease on the CNS and opportunities for central neuromodulation.Nature reviews. Neuroscience · 2026Review
- Running on empty: Factors underpinning impaired cardiac output reserve in heart failure with preserved ejection fraction.Experimental physiology · 2025Review
- Bayliss Starling Prize Lecture 2023: Neuropeptide-Y being 'unsympathetic' to the broken hearted.The Journal of physiology · 2025Article
- Clinical neurocardiology: defining the value of neuroscience-based cardiovascular therapeutics - 2024 update.The Journal of physiology · 2025Review
- Neurocardiology: translational advancements and potential.The Journal of physiology · 2025Review
- Bioelectronic Medicines-A Novel Approach of Therapeutics in Current Epoch.Current pharmaceutical design · 2025Review
- Carotid Baroreceptor Stimulation Ameliorates Pulmonary Arterial Remodeling in Rats With Hypoxia-Induced Pulmonary Hypertension.Journal of the American Heart Association · 2024Article
- The coming era of neuromodulation therapies: expectations for baroreceptor stimulation.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Contrasting effects of carotid baroreceptor stimulation on regional sympathetic drive in chronic human heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Neural control of the circulation during exercise in heart failure with reduced and preserved ejection fraction.American journal of physiology. Heart and circulatory physiology · 2023Review
- A Comparative Review of Vagal Nerve Stimulation Versus Baroreceptor Activation Therapy in Cardiac Diseases.Cureus · 2023Review
- Endothelial, Vascular and Sympathetic Alterations as Therapeutic Targets in Chronic Heart Failure.Biomedicines · 2023Review
- Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario.ESC heart failure · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF. METHODS AND
resultsIn a single-centre, open-label evaluation, patients with NYHA class III HF, EF <40%, optimized medical therapy, and ineligible for cardiac resynchronization received BAT for 6 months. Efficacy was assessed with serial measurement of muscle sympathetic nerve activity (MSNA) and clinical measures of quality of life and functional capacity. Eleven patients participated in the trial. MSNA was reduced over 6 months from 45.1 ± 7.7 to 31.3 ± 8.3 bursts/min and from 67.6 ± 12.7 to 45.1 ± 11.6 bursts/100 heartbeats, decreases of 31% and 33%, respectively (P < 0.01). Concomitant improvements occurred in baroreflex sensitivity, EF, NYHA class, quality of life and 6 min hall walk (6 MHW) distance (P ≤ 0.05 each). On an observational basis, hospitalization and emergency department visits for worsening HF were markedly reduced. One complication, perioperative anaemia requiring transfusion, occurred during the study.
conclusionBAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.